Munich, Germany, 27 February 2012. WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that the US Food and Drug Administration (FDA) approved the protocol amendment for the pivotal Phase III …
WILEX reports on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process
Munich, 17 June 2011. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced that the Pre-BLA Meeting with the American Food and Drug Administration planned for the second …
WILEX grants exclusive US commercialisation rights for RENCAREX® to Prometheus
Munich, Germany, 02 May, 2011. WILEX AG (ISIN DE0006614720, Frankfurt Stock Exchange) announced the granting of US commercialisation rights for RENCAREX® (Girentuximab) to Prometheus Laboratories Inc. …
WILEX veröffentlicht Finanzbericht für erstes Quartal 2011
• Finanzzahlen im Rahmen der Planung • Gesellschafterdarlehen erhalten • Zwischenanalyse zur Wirksamkeit für RENCAREX® gestartet • Akquisition der Heidelberg Pharma AG erfolgreich …
WILEX reports on the successful financial year 2010
• Strategic expansion of the value chain • Significant progress of all clinical projects • Financials in line with guidance Munich, Germany, 22 February 2011. WILEX AG (ISIN DE0006614720 / Frankfurt …
WILEX announces start of interim analysis for its Phase III ARISER registration trial with RENCAREX®
Munich, Germany, 24 January, 2011. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced the achievement of a major clinical milestone. Over 340 recurrences have now been …